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Influence of Folate on Arterial Permeability and Stiffness 
in the Absence or Presence of Hyperhomocysteinemia
J. D avid Sym ons, U ssam a B. Zaid, Christian N. A thanassious, Adam  E. M ullick,
Steven R. Lentz, John C. R utledge
O bjective— Elevated plasm a total hom ocysteine (tHcy) is associated with risk for cardiovascular disease. A com mon cause 
o f m ild hyperhom ocysteinem ia (HHcy) is folate deficiency. W e sought to determ ine whether folate deficiency per se 
increases arterial perm eability (quantitative fluorescence m icroscopy) and stiffness (vessel elastigraph), and whether the 
effects o f folate deficiency are m ore severe in the presence o f m ild HHcy.
M ethods a n d  R esu lts— H eterozygous cystathionine /3-synthase (CBS)-deficient m ice (C B S : ) and their w ild-type 
litterm ates (C B S+/+) were fed chow containing either standard (Con) or relatively low am ounts o f folate (LF) for 18 ± 3  
weeks. Liver folate (n g  folate/g liver) and tHcy (/liM), respectively, w ere 12±  1 and 8± 1  in C B S+/+ Con m ice (n =  12), 
and 8 ± 1  and 8± 1  in C B S+/+ LF animals (n = 5 ). Carotid arterial perm eability was =»38% greater (P < 0 .0 5 ) in C B S+/+ 
LF versus Con mice, but vascular stiffening was unaltered. Liver folate and tHcy, respectively, were 13±  1 and 11 ±1 
in C B S+/~ Con m ice (n =  16), and 8 ± 1  and 1 6 ± 3  in C B S+/~ LF animals (n = 6 ). Carotid arterial dextran accum ulation 
was =«31% greater, and maximal strain in aortae was =»20% lower (both P < 0 .0 5 ) in C B S+/~ LF versus Con mice.
C on clu sion — Taken together, low folate (P < 0 .05 ) com bined with m ild HHcy (P < 0 .0 5 ) in C B S+/~ m ice produced more 
arterial dysfunction com pared with low folate alone (ie, C B S+/+ mice). These findings may be particularly relevant to 
elderly individuals because tHcy and deficiencies o f folate metabolism increase with age. (A rter io sc le r  T hrom b V ase  
B iol. 2006;26:814-818.)
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I " 1 lcvation of plasma total homocystcinc (tHcy) is associated 
J—/with an increased risk of cardiovascular disease, but the 
underlying mechanisms arc not well understood.1 Worldwide, 
the most common cause of mild hyperhomocysteinemia (HHcy) 
is deficiency of folate.2-3 Some4- 8 but not all9-10 studies suggest 
that folate deficiency contributes to cardiovascular disease in a 
manner that is independent of its ability to elevate plasma 
tHcy.11 We have reported that HHcy evoked by folate depletion 
increases arterial permeability and stiffness in rats.12
Homocystcinc is metabolized via the transsulfuration and 
rcmcthylation pathways (Figure 1 ).13 Cystathionine j3-synthasc 
(CBS) is the rate-limiting enzyme for homocystcinc metabolism 
via the transsulfuration pathway. Heterozygous CBS-dcficicnt 
(CBSf/~) mice arc predisposed to elevated tHcy concentra­
tions.14 Folate is required for homocystcinc metabolism via the 
rcmcthylation pathway. When folate consumption and/or ab­
sorption arc compromised, plasma tHcy bccomcs elevated.15
In the present study, we sought to determine whether folate 
dcficicncy per sc increases arterial permeability and stiffness 
in mice, and whether the cffccts o f folate dcficicncy arc more
severe in the prcscncc of mild HHcy. CBS mice and their 
wild-type littermates (ie, C B S f/f micc) were fed chow 
containing cither standard or relatively low amounts of folate. 
Arterial permeability and stiffness were assessed bccausc of 
their potential rclcvancc to atherosclerotic cardiovascular 
disease. In this regard, greater endothelial cell layer perme­
ability facilitates arterial lipoprotein accumulation and thus 
may contribute to lesion development and/or severity, and 
decreased arterial compliance increases aftcrload to an extent 
whereby myocardial oxygen demand is elevated inappropri­
ately.16-17 Comparing C B S f/f micc on these 2 diets allowed 
us to test the hypothesis that low folate per sc influences 
arterial permeability and stiffness. By also studying CBS 
micc that consumed standard or low-folatc chow, wc were 
able to test the hypothesis that arterial dysfunction produced 
by low folate is more severe in the prcscncc of mild HHcy.
Materials and Methods
All protocols used in this study were approved by the Animal Use 
and Care Committee at the University of California, Davis and
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Figure 1. The remethylation and transsulfuration pathways of 
homocysteine metabolism. Homocysteine remethylation is 
impaired when dietary folate is reduced. Homocysteine transsul­
furation is impaired when cystathionine beta synthase enzyme 
activity is deficient. SAM, S-adenosylmethionine; SAH, 
S-adenosylhomocysteine; MTHF, methyltetrahydrofolate; MS, 
methionine synthase; CBS, cystathionine beta synthase;
CBS ' \  heterozygous for CBS deficiency.
conformed to guidelines set by the American Physiological Society 
and Animal Welfare Act.
Experimental Animals and Diets
Heterozygous CRS-deficient mice (CBS- '" )14 and their wild-type 
(CBS ' ) littermates were housed individually under controlled 
temperature (23°C) and light conditions (12:12-hour light;dark 
cycle). CBS mice were crossbred to C57BL/6J mice (The Jackson 
Laboratory. Bar Harbor. Me) for at least 8 generations. Oenotyping 
for the targeted CBS allele was performed by polymerase chain 
reaction.14
At the time of weaning. CBS A mice were fed a commercially 
available (Harlan Teklad. Madison. Wis) amino acid-defined diet 
containing either 0.75 mg (CBS Control. Con; n =  12) or 0.15 mg 
(CBS A low folate. LF; n = 5 ) folate per 100 g o f chow. CBS A mice 
were divided into 2 groups and treated similarly, ie. CBS Con 
(n=  16) and CBS LF (n=6). Because homocysteine transsulfura­
tion is compromised in CBS mice, mild HHcy was predicted when 
these animals consumed the LF diet. All mice were given the 
antibiotic succinylsulfathiazole (1 %) to eradicate intestinal micro­
flora that are capable o f synthesizing folate endogenously.
General Procedures
After 18±3 weeks on the respective diets, fasted mice were 
anesthetized (0.05 mg/g sodium pentobarbital, intraperitoneal). the 
chest opened, and blood was collected from the right ventricle to 
measure plasma tHcy. tHcy was measured using high-performance 
liquid chromatography (HPLC) with fluorescence detection1218 and 
refers to the combination of free reduced homocysteine («=19f of 
total), mixed disulfides (20®/f to 30®/f o f total), and protein-bound 
homocysteine (70% to 80% of total).19 Samples of liver (for folate 
analysis) and thoracic aorta (to measure arterial elasticity) were 
removed, snap-frozen in liquid nitrogen (LN,). and stored at -8 0 °C . 
The right and left common carotid arteries were excised and prepared 
immediately to assess vascular permeability. Liver folate was mea­
sured using a conventional microbiological assay12-20 because it is 
more indicative of long-term folate status and is less susceptible to 
fluctuations in metabolism than serum folate.12-21-22
Measurement of Arterial Permeability
Carotid arteries were placed in a microscope viewing chamber- 
containing Krebs Henseleit (KH) buffer (pH 7.4. 37°C). The proxi­
mal and distal ends of each artery were cannulated and perfused with
1% bovine serum albumin at 2 mL/min (37°C. pH 7.4) for 15 
minutes using a peristaltic pump. During this equilibration period, 
both arteries were viewed under a fluorescence microscope con­
nected to a photometer and video camera while fluorescence inten­
sity was recorded on a computer and chart recorder. The assessment 
of vascular permeability using quantitative fluorescence microscopy 
involves 3 perfusion phases. In the first, the artery was perfused (2 
mL/min. 100 mm Hg. 37°C. pH 7.4. 8 minutes) with clear, nonfluo- 
rescent KH buffer plus 1% bovine serum albumin to measure 
baseline fluorescence intensity. Second. 4400 MW  dextran mole­
cules (estimated Stokes diameter. 1.4 nm; 42 g/mL in perfusate) 
labeled with tetramethylrhodamine isothiocyanate (TRITC) (0.0833 
mg/mL TRITC-dextran in perfusate. 494 nm excitation maximum. 
518 nm emission maximum) were perfused through the arterial 
lumen for 5 minutes and viewed/recorded through an inverted light 
microscope. Dextran was used as the reference molecule because this 
nonlipid particle does not bind specifically to the artery wall. During 
the second phase a rapid increase in intraluminal fluorescence 
intensity occurs as TRITC-labeled dextran fills the artery lumen. In 
the third phase, the artery was perfused for 8 minutes with nonfluo- 
rescent buffer to wash the TRITC-labeled dextran out o f the lumen. 
The 3 phases are collectively termed a perfusion "run.”
The washout phase (ie. phase 3) is analyzed as 2 distinct 
processes. The first rapid washout represents dextran exiting the 
vessel lumen, whereas the second slower washout represents dextran 
exiting the vessel wall. Arterial permeability is estimated by the 
amount o f TRITC-labeled dextran that accumulates in the arterial 
wall (I, accumulation). Calculating I, accumulation involves finding 
the intersection o f tangents drawn to approximate the rapid and slow 
washout phases. To determine I, accumulation rate. I, accumulation 
is divided by time of perfusion. Fluorescence values then are 
converted from millivolts/min to ng TRITC-dextran/cm2 per min 1 
by knowing the: (1) surface area o f the vessel in the photometric 
window; (2) arterial lumen volume of the vessel in the photometric 
window; (3) fluorescence intensity at time 0 (I, 0) that occurs at the 
beginning of TRITC perfusion; and (4) concentration o f dextran in 
the perfusate. I, accumulation rates were performed in triplicate for 
each vessel, and the values were averaged. 12~’-2S
Measurement of Vascular Stiffening
Vascular stiffening was estimated using a modified vessel myograph, 
termed an elastigraph.12 After vessels were thawed overnight. 2 
stainless steel rods were inserted in a parallel manner through the 
lumen of a 1-mm segment o f thoracic aorta while the vessel was 
immersed in KH buffer. One rod was fixed to a force transducer 
while the other was attached to a motorized controller. The elasti­
graph allows the vessel to be stretched radially at a constant rate until 
breakage while vessel tension is recorded via a force transducer. In 
preparation for each stretch, aortic segments were preconditioned 3 
times at «=10% of their maximal load (maximal tension at the vessel 
breaking point). Stress (vessel tension development divided by 
vessel area; N/mm2) versus strain [(vessel width at breakage—vessel 
width at start) divided by vessel width at start; %} curves were 
generated using three 1-mm aortic segments from each animal and 
the results were averaged. From these curves maximal stress (ie. 
stress at vessel breakage; N/mm2) and maximal strain (ie. strain at 
vessel breakage; ultimate extensibility. °/r) were calculated. Because 
samples from each group were thawed and analyzed together, any 
nonspecific side effects o f freezing should have influenced both 
groups in an equivalent manner. These methods have been used 
previously by our laboratory and others.1217'26'29'30
Drugs and Solutions
Unless noted otherwise, all chemicals were purchased from Sigma 
Chemical Co (St. Louis. Mo). KH solution contained (in mmol/L) 
NaCl (116). KC1 (5). CaCl, • H ,0  (2.4). MgCl, (1.2). N H ,P 04 (1.2). 
glucose (11) and bovine serum albumin ( 19f).
Statistical Analyses
Animal and vessel characteristics, dextran accumulation rate, maxi­
mal strain, and maximal stress were compared among CBS A Con.
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CBS+/+ LF, CBS+/_ Con, and CBS+/_ LF groups using a 1-way 
ANOVA and a Tukey post-hoc test. Results are presented as 




Body weight (g) was similar between CBS+/+ Con (24±1) 
and LF (23±1) mice, and CBS+/“ Con (22±1) and LF 
(21 ±  1) animals. Whereas liver folate (/xg/g liver) was ^33%  
lower in CBS+/+ LF versus CBS+/+ Con mice, tHcy (juM) was 
similar between groups (Figure 2A and 2B). These results 
allowed us to evaluate the independent contribution(s) from 
low folate to arterial permeability and stiffness in CBS+/+ 
animals without HHcy.
In CBS+/_ LF mice, liver folate (jag/g liver) was ^38%  
lower and tHcy (j jM)  was ^  1.5-fold higher compared with 
CBS+/_ Con animals (Figure 2C and 2D). These results 
allowed us to determine whether the effects of low folate are 
more severe in the presence of mild HHcy.
Arterial Permeability
Real-time measurements of dextran accumulation in the 
arterial wall were made using methods whereby flow rate, 
hydrostatic pressure, pH, temperature, and superfusate and 
perfusate compositions were controlled to simulate physio­
logical conditions.12 23-28 In CBS+/+ mice, carotid arterial 
dextran accumulation was ^38%  greater in LF versus Con 
animals (Figure 3A). Likewise, arterial permeability was 
^31%  greater in CBS+/_ LF versus Con mice (Figure 3B). 
Thus, low folate is a major contributor to increasing arterial 
permeability and no further increase was observed in this 
variable when low folate and HHcy existed concomitantly.
Arterial Stiffening
The passive elastic properties of thoracic aortae were quan­
tified using a vessel elastigraph modified to measure arterial 
elasticity.12-1730 This is a sensitive procedure compared with 
traditional compliance/distensibility methods.17 Maximal 
strain was similar in thoracic aortae from CBS+/+ LF and
A. CBS +/+ mice 
Arterial permeability
■  ■  ■ ■
B. CBS+/- mice 
Arterial permeability
Con LF Con LF
Figure 3. Arterial permeability was greater in CBS+/+ (A) and 
CBS+/_ mice (B) that consumed low-folate (LF) vs standard 
(Con) rodent chow. CBS+/_ mice, mice that are heterozygous for 
cystathionine beta synthase deficiency; CBS+/+ mice, wild-type 
littermates of CBS+/_ mice. *P<0.05 HHcy vs Con. Values are 
mean±SEM.
CBS+/+ Con mice (Figure 4A) but was ^20%  lower in 
thoracic aortae from CBS+/_ LF versus CBS+/_ Con mice 
(Figure 4C). Lower maximal strain indicates less distensible 
vessels, an outcome of increased vascular stiffening.31 Max­
imal stress was similar among groups (Figure 4B and 4D). In 
comparison with the pathophysiological alterations on arterial 
permeability, increased vascular stiffening was dependent on 
both low-folate status and mild HHcy.
Discussion
Our findings support the hypotheses that low folate indepen­
dently increases arterial permeability, and that both low folate 
and mild HHcy contribute to the severity of arterial stiffness. 
The clinical relevance of these findings is underscored by 
observations that tHcy increases with age,32 and low to 
low-normal concentrations or deficiencies of folate resulting 
from reduced intake and/or decreased absorption are not 
uncommon in elderly individuals and/or populations that lack 
dietary fortification with folic acid.33 34
We manipulated the remethylation pathway of homocys­
teine metabolism in CBS+/+ and CBS+/_ mice via dietary 
means to generate experimental groups to test our hypotheses. 
Dietary folate restriction in CBS+/+ mice produced significant 
reductions in liver folate but did not impair homocysteine 
remethylation to an extent that elevated plasma tHcy. There­
fore, CBS+/+ mice were used to test the hypothesis that low
Figure 2. tHcy was similar but liver folate was reduced in 
CBS+/+ mice that consumed low-folate (LF) vs standard (Con) 
chow (A,B). tHcy was elevated and liver folate was reduced in 
CBS+/_ LF vs Con mice (C,D). *P<0.05 LF vs Con. Values are 
mean±SEM. CBS+/_ mice, mice heterozygous for cystathionine 
beta synthase deficiency; CBS+/+ mice, wild-type littermates of 
CBS+/_ mice.
Figure 4. Maximal strain (A) and maximal stress (B) were similar 
in CBS+/+ mice that consumed low-folate (LF) and standard 
(Con) rodent chow. Maximal stress (D) was similar between 
groups but maximal strain (C) was lower in CBS+/_ LF vs Con 
mice. *P<0.05 LF vs Con. Values are mean±SEM. CBS+/_ 
mice, mice heterozygous for cystathionine beta synthase defi­
ciency; CBS+/+ mice, wild-type littermates of CBS+/_ mice.
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folate per sc evokes arterial dysfunction. In CBS+'~ micc. 
dietary folate restriction produced reductions in liver folate 
and elevations of plasma tHcy. This experimental approach 
allowed us to examine the combined influcncc of mild HHcy 
plus low folate on arterial permeability and stiffness.
Arterial Permeability: The Independent Influence 
of Low Folate
One of the initial steps in the development of athcrosclcrosis 
is endothelial dysfunction. This is frequently manifested as 
increased endothelial ccll permeability. Multiple previous 
studies have shown that increased endothelial ccll layer 
permeability is accompanicd by the accumulation of low- 
density lipoprotein in the artery wall.16'35 Increased perme­
ability and lipoprotein accumulation could contribute to 
lesion development and/or severity.16 Earlier wc observed 
that HHcy-cvokcd by folate depletion increases arterial per­
meability in rats.12 Bccausc HHcy and low folate existed 
together in that study, their rcspcctivc contributions to vas­
cular dysfunction could not be disccrncd. Our current results 
support the previously untested hypothesis that low folate per 
sc increases arterial permeability. In CBS+,+ micc ^33%  
reductions in liver folate were associated with 38% increases 
in carotid arterial permeability. Importantly. tHcy was similar 
between groups.
A strong rationale existed for performing this experiment. 
For instance, patients with low scrum folate, but normal 
homocystcinc. arc known to have increased pcriphcral/coro- 
nary vascular disease.4 Moreover, numerous investigations 
have shown that exogenous folic acid improves endothelial 
function in patients with cardiovascular disease in the prcs­
cncc36-38 or abscncc37-39 of homocystcinc lowering. To­
gether. these studies suggest a dircct bcncficial action of folic 
acid on vascular function. One proposed mcchanism is that 
the activc form of folic acid. 5-mcthyltctrahydrofolatc. in­
creases nitric oxide production, rcduccs 0 2~ generation, and 
directly scavcngcs 0 2~.40 As such, it follows that a critical 
reduction in folate may increase 0 2~ generation and dccrcasc 
nitric oxide bioavailability to an extent that elevates arterial 
permeability. In support of this model, wc have found that when 
tissue folate was rcduccd by 50% in rats, liver lipid and protein 
oxidation were elevated, vascular 0 2~ generation was increased, 
and vascular nitric oxide bioavailability was rcduccd.5
Arterial Stiffening: The Independent Influence 
of Low Folate
Arterial stiffness is a risk factor for cardiovascular disease41 
and is observed in patients with athcrosclcrosis. diabetes, and 
hypertension.42 The cffccts of low folate per sc on arterial 
stiffness have not been investigated, but several studies have 
examined whether folic acid supplementation improves this 
index of vascular function. In placcbo-controllcd. random­
ized. clinical trials, common carotid arterial stiffness was not 
altered in patients with end-stage renal disease43 or in healthy 
individuals44 who consumed folic acid for 1 to 2 years. In a 
third study, increased systcmic arterial compliancc was ob­
served in folatc-rcplctc individuals who consumed 5 mg folic 
acid/day for 3 weeks compared with a matching placcbo.45 
Collcctivcly. the mixed results o f these clinical trials do not
provide a d ea r picture regarding the cffccts of folic acid 
supplementation on arterial stiffness. Using CBS+,+ micc. wc 
examined the hypothesis that low-folatc independently in­
creases vascular stiffness in the abscncc of HHcy.29 Wc found 
that when liver folate was rcduccd by ^33% . no diffcrcnccs 
in arterial stiffening were observed in CBS+,+ micc fed the LF 
diet. A limitation of this finding is that the severity of 
folatc-lowcring may not have been sufficient to influcncc 
arterial stiffness, despite a major cffcct on permeability. 
When wc attempted to dccrcasc liver folate to a greater 
degree in CBS+,+ micc. rcmcthylation was impaired to an 
extent that plasma tHcy was elevated, making it impossible to 
test the independent cffcct of low folate (data not shown).
Arterial Permeability and Stiffness: The 
Combined Influence of HHcy Plus LF
When 1.5-fold tHcy elevations were combined with ^38%  
reductions of liver folate in CBS+,~ LF micc. both arterial 
permeability and stiffness increased. These findings suggest 
that the vascular conscqucnccs of low folate arc more severe 
when they cocxist with mild HHcy. Increased arterial stiff­
ening may result from the accumulation of advanced glyca- 
tion end products (AGEs) that occurs during noncnzymatic 
glycation of clastin or collagcn within the vascular wall.29-31'46 
During this proccss. oxidant stress produced by HHcy may 
stimulate the incorporation of glucosc-dcrivcd crosslinks 
such as pcntosidinc between collagcn fibers. Collagcn cross­
linking is one mcchanism thought to be responsible for 
rcduccd vascular distcnsibility in diabetes and athcrosclcro­
sis. and could be operative in response to HHcy. In this 
regard, others have reported increased AGE rcccptor expres­
sion in micc with HHcy.10 and wc have shown that pcntosi­
dinc is elevated 60-fold in arterial tissue from rats with HHcy 
that possess local and global indiccs of increased oxidant 
stress.12
In summary, wc observed that reduction in liver folate 
resulted in increased arterial permeability, and that elevation 
of tHcy combined with reduction of liver folate produced 
both increased arterial permeability and stiffness. Greater 
arterial dysfunction in the setting of mild HHcy and low 
folate may be clinically relevant, cspccially for elderly 
individuals who may have dcficicncics of folate resulting 
from a number of factors (eg. rcduccd intake, impaired 
absorption, interactions with medications).33 These factors 
may be cspccially important in countries that do not rccom- 
mend voluntary folate fortification of products by food 
manufacturers.34'47
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